Associated Genetic Biomarkers
Signal transducer and activator of transcription 6, interleukin-4 induced (STAT6) is a gene that encodes a protein that functions as a transcription activator. The protein is specifically important for in IL4 mediated biological responses. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
STAT6 is altered in 0.87% of all cancers with lung adenocarcinoma, solitary fibrous tumor, follicular lymphoma, colon adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in STAT6 are STAT6 Mutation (1.35%), STAT6-NAB2 Fusion (0.13%), STAT6 Amplification (0.20%), STAT6 D419G (0.14%), and STAT6 D419H (0.04%) .
STAT6 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains STAT6 status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with STAT6 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is STAT6 Mutation .
Irinotecan and sorafenib are the most frequent therapies in trials with STAT6 as an inclusion criteria .
Significance of STAT6 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.